Journal of Clinical Endocrinology & Metabolism, Vol 80, 1278-1282, Copyright © 1995 by Endocrine Society

ARTICLES

Do androgens regulate growth hormone-binding protein in adult man?

TP Ip, DM Hoffman, AJ O'Sullivan, KC Leung and KK Ho
Garvan Institute of Medical Research, St. Vincent's Hospital, Sydney, New South Wales, Australia.

To determine whether adult serum GH-binding protein (GHBP) is regulated by androgen, serum GHBP concentrations were compared between 20 normal and 18 hypogonadal men matched for age and body mass index, and the effect of im testosterone treatment (250 mg testosterone enanthate) on GHBP levels in the 18 hypogonadal men was studied. Nine of the hypogonadal subjects had coexistent GH deficiency. Serum GHBP concentration was measured by a ligand immunofunctional assay. The mean serum GHBP level in untreated hypogonadal men was not significantly different from that of normal men (0.98 +/- 0.15 vs. 1.17 +/- 0.16 nmol/L). The mean serum insulin-like growth factor I (IGF-I) level was significantly lower in the hypogonadal men (132 +/- 22 vs. 206 +/- 17 ng/mL; P < 0.01). Basal testosterone (3.7 +/- 0.7 nmol/L) in hypogonadal men increased during treatment to a mean level of 29.1 +/- 2.8 nmol/L, which was not significantly higher than that in normal men (22.6 +/- 1.9 nmol/L). The mean serum GHBP level in hypogonadal men fell significantly during treatment to 0.60 +/- 0.11 nmol/L (P = 0.0003), whereas the serum IGF-I level rose significantly to 151 +/- 26 ng/mL (P < 0.04). The decrease in GHBP level was significant in both the GH-sufficient and GH-deficient subjects (P < 0.02 in both instances), whereas the increase in IGF-I level was significant in the GH-sufficient group (199 +/- 22 to 235 +/- 29 ng/mL; P < 0.04) but not in the GH-deficient group (53 +/- 7 to 55 +/- 5 ng/mL; P > 0.8). Thus, serum GHBP is normal in hypogonadal men but is reduced by testosterone treatment irrespective of endogenous GH-secretory status. It was concluded that the effect of testosterone on GHBP is pharmacological and occurs independent of GH mediation.

This article has been cited by other articles:

				J. Gibney, T. Wolthers, G. Johannsson, A. M. Umpleby, and K. K. Y. Ho Growth hormone and testosterone interact positively to enhance protein and energy metabolism in hypopituitary men Am J Physiol Endocrinol Metab, August 1, 2005; 289(2): E266 - E271. [Abstract] [Full Text] [PDF]

				S. W. van Thiel, J. A. Romijn, A. M. Pereira, N. R. Biermasz, F. Roelfsema, A. van Hemert, B. Ballieux, and J. W. A. Smit Effects of Dehydroepiandrostenedione, Superimposed on Growth Hormone Substitution, on Quality of Life and Insulin-Like Growth Factor I in Patients with Secondary Adrenal Insufficiency: A Randomized, Placebo-Controlled, Cross-Over Trial J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3295 - 3303. [Abstract] [Full Text] [PDF]

				G. Noe, J. Suvisaari, C. Martin, A.J. Moo-Young, K. Sundaram, S.I. Saleh, E. Quintero, H.B. Croxatto, and P. Lahteenmaki Gonadotrophin and testosterone suppression by 7{alpha}-methyl-19-nortestosterone acetate administered by subdermal implant to healthy men Hum. Reprod., September 1, 1999; 14(9): 2200 - 2206. [Abstract] [Full Text] [PDF]

				A. Giustina and J. D. Veldhuis Pathophysiology of the Neuroregulation of Growth Hormone Secretion in Experimental Animals and the Human Endocr. Rev., December 1, 1998; 19(6): 717 - 797. [Abstract] [Full Text]

				M. Christopher, F. L. Hew, M. Oakley, C. Rantzau, and F. Alford Defects of Insulin Action and Skeletal Muscle Glucose Metabolism in Growth Hormone-Deficient Adults Persist after 24 Months of Recombinant Human Growth Hormone Therapy J. Clin. Endocrinol. Metab., May 1, 1998; 83(5): 1668 - 1681. [Abstract] [Full Text]